Drug Trial Radar · NCT05158699
Effectiveness of Periocular Drug Injection in CATaract Surgery
Last checked: Nov 20, 2026Latest source record: Nov 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
628
Actual
Start
Oct 13, 2021
Primary completion
Aug 13, 2024
Study completion Aug 13, 2024
Sponsor
- Lead sponsor
- Luigi RondasAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- European Society of Cataract and Refractive Surgeons
- First posted
- Dec 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (care provider, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cystoid macular edema (CME) is a major cause of suboptimal postoperative visual acuity after cataract surgery. Topical steroidal and nonsteroidal anti-inflammatory drugs (NSAIDs) are used to prevent CME. However, noncompliance with eye drops may compromise the effectiveness of treatment. Dropless periocular drug delivery during cataract surgery may improve the outcomes and cost-effectiveness of cataract surgery, and may alleviate the burden on homecare organizations.
Conditions
- Macular Edema
- Cystoid Macular Edema
- Retinal Disease
- Cataract
- Lens Diseases
- Eye Diseases
Interventions
BromfenacDrug
Bromfenac topical eye drops (Yellox)
DexamethasoneDrug
Dexamethasone topical eye drops
Triamcinolone AcetonideDrug
0.25ml of 40mg/ml (10mg) triamcinolone acetonide (Triesence/Vistrec) will be injected subconjunctivally
Ketorolac-Phenylephrine Ophthalmic 0.3%-1% Intraocular SolutionDrug
Omidria is added to the irrigation fluid used during cataract surgery. At the end of surgery, the anterior chamber will be filled with the ketorolac solution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in central subfield mean macular thickness as a measurement of efficacyTime frame: Baseline, 6 weeks postoperatively
Locations
10 sites in 4 countries. Site status is shown where the registry gives one.
Hospital of the Brothers of Saint John of God
Vienna, Austria
Vienna Institute for Research in Ocular Surgery, Hanusch Krankenhaus
Vienna, Austria
Goethe University
Frankfurt am Main, Germany
Amphia
Breda, Netherlands
Deventer Ziekenhuis
Deventer, Netherlands
Zuyderland Medisch Centrum
Heerlen, Netherlands
University Eye Clinic Maastricht UMC+
Maastricht, Netherlands
Canisius Wilhelmina Ziekenhuis Nijmegen
Nijmegen, Netherlands
Elisabeth-Twee Steden Ziekenhuis, locatie Elisabeth
Tilburg, Netherlands
University Hospital Coimbra
Coimbra, Portugal
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.